Meet the team

Co-Founder Directors & members of the Leadership Team

Dr Steve McConchie


Steve has worked in clinical development for nearly 25 years with AZ where he successfully delivered numerous oncology and haematology clinical development programmes.

Since forming Aptus Clinical, he and his expert team continue to support the design, conduct and delivery of innovative early phase clinical studies in oncology and rare diseases for a broad range of clients.

He is a member of the Scientific Innovation and Advisory Committee of the Bioindustry Association.

Jonathan Lewis

Chief Commercial Officer

A time proven project leader and line manager with 30 years’ industry experience in UK and Sweden. During his career he has worked across a broad range of disciplines, including clinical, laboratory and sales and marketing, in numerous therapeutic areas, including respiratory, oncology, CNS, infection and ophthalmology.

Since co-founding Aptus Clinical, Jonathan has helped build the business and grow the client portfolio.

Anita Cawley

Chief Governance Officer

Anita trained as a pharmacist and has 22 years’ clinical research experience across all development phases and with various pharma companies including GSK, Sanofi Winthrop, 3M and AstraZeneca.

Since co-founding Aptus Clinical, Anita has brought her decades of functional experience to establish a highly effective clinical operations team as well as implementing a fully integrated procedural infrastructure for client support.

Additional members of Leadership Team

Karen Sanville

Head of Clinical Services

Karen Sanville is our Head of Clinical Services. She spent 26 years at AstraZeneca, where she headed up UK Clinical Operations before moving to Quintiles as Vice President, Project Leadership Oncology.

Tessa Clarke

Risk, Governance and Compliance Director

Tessa Clarke is our Risk, Governance and Compliance Director and has more than 20 years’ experience in clinical research. She has also been extensively involved in supporting and managing our Quality Management System.

Clinical Development Experts

Dr Glen Clack

Chief Medical Officer

As Chief Medical Officer, Glen ensures the highest standards are achieved in the design, implementation and medical monitoring of clinical studies.

Glen has experience in all phases of clinical development, but now focusses on translational medicine, overseeing the early development of small molecule anti-cancer compounds. Areas of expertise include hormone manipulation, DNA damage repair, MTOR/PI3K/AKT pathway, anti-sense oligonucleotide and tumour genetic drivers.

Glen holds honorary academic positions at Manchester and Sheffield Universities.

Dr Paul Elvin

Chief Translational Science Officer

As Chief Translational Science Officer, Paul provides specialist bioscience and translational science input to preclinical and clinical drug projects.

During his 27 years’ experience in cancer drug discovery at AZ, Paul provided successful scientific leadership for both small molecule and therapeutic antibody projects, from target identification through early phase clinical studies. He has broad experience in the design and implementation of translational science programs, including due diligence for late stage preclinical and clinical opportunities.

Jane Hayhurst

Director of Regulatory Affairs

As Director of Regulatory Affairs, Jane has over 30 years of experience in developing and executing global regulatory strategies across phase I to IV, particularly in the area of oncology. She has a proven track record of finding novel solutions to challenging drug development issues, as well as Paediatric and Orphan Drug submissions and vast experience in the planning and conduct of key regulatory agency meetings (FDA, EMA, and national agencies).

Nicola Little

Chief Statistical Officer

As Chief Statistical Officer, Nicola is responsible for the statistical integrity of clinical studies and supporting submissions to international regulatory authorities.

While Statistical Science Director at AZ, she was accountable for the provision of statistical input and strategy to drug development programmes for both oncology and infection, spanning Phase I to IV. Nicola designed and defended the Tagrisso® programme to the FDA and EMA.